A. Karim

发表

Biopharmaceutical profile of diclofenac-misoprostol combination tablet, Arthrotec.

A. Karim, M. Smith, 1992, Scandinavian journal of rheumatology. Supplement.

Bladder puncture in newborns--a bacteriological study.

A. Karim, S. Djojohadipringgo, R. H. Abdul Hamid, 1976, Paediatrica Indonesiana.

Population Pharmacokinetics Analysis of Vigabatrin in Adults and Children with Epilepsy and Children with Infantile Spasms

K. Kowalski, D. Tolbert, A. Karim, 2014, Clinical Pharmacokinetics.

Inverse Nonlinear Pharmacokinetics of Total and Protein Unbound Drug (Oxaprozin): Clinical and Pharmacokinetic Implications

A. Karim, 1996, Journal of clinical pharmacology.

A Review and Assessment of Potential Sources of Ethnic Differences in Drug Responsiveness

T. Bjornsson, J. Wagner, D. Sonnichsen, 2003, Journal of clinical pharmacology.

Coadministration of Pioglitazone or Glyburide and Alogliptin: Pharmacokinetic Drug Interaction Assessment in Healthy Participants

Q. Mekki, E. Wann, A. Karim, 2009, Journal of clinical pharmacology.

Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects.

Q. Mekki, E. Wann, A. Karim, 2010, International journal of clinical pharmacology and therapeutics.

Single-Center Evaluation of the Single-Dose Pharmacokinetics of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Renal Impairment

R. Preston, D. Sica, O. Lenz, 2013, Clinical Pharmacokinetics.

Oral Antidiabetic Drugs: Bioavailability Assessment of Fixed‐Dose Combination Tablets of Pioglitazone and Metformin. Effect of Body Weight, Gender, and Race on Systemic Exposures of Each Drug

A. Karim, C. Cao, Zhen Zhao, 2007, Journal of clinical pharmacology.

Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog.

A. Karim, C. Kook, R. Novotney, 1978, Drug metabolism and disposition: the biological fate of chemicals.

Effects of food on the bioavailability of theophylline from controlled-release products in adults.

A. Karim, 1986, The Journal of allergy and clinical immunology.

Suitability of the dog as an animal model for evaluating theophylline absorption and food effects from different formulations

K. Kowalski, A. Karim, G. Schoenhard, 1990 .

Single‐Center Evaluation of the Pharmacokinetics and Safety of the Angiotensin II Receptor Antagonist Azilsartan Medoxomil in Mild to Moderate Hepatic Impairment

R. Preston, A. Karim, A. Alonso, 2017, Journal of clinical pharmacology.

Oxaprozin and Piroxicam, Nonsteroidal Antiinflammatory Drugs with Long Half‐Lives: Effect of Protein‐Binding Differences on Steady‐State Pharmacokinetics

F. Mcmahon, J. Wilton, A. Karim, 1997, Journal of clinical pharmacology.

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects.

Q. Mekki, E. Wann, A. Karim, 2008, Clinical therapeutics.

Oral Antidiabetic Drugs: Effect of Food on Absorption of Pioglitazone and Metformin From a Fixed‐Dose Combination Tablet

A. Karim, A. Laurent, L. Schwartz, 2007, Journal of clinical pharmacology.

Disposition Kinetics and Tolerance of Escalating Single Doses of Ramelteon, a High‐Affinity MT1 and MT2 Melatonin Receptor Agonist Indicated for Treatment of Insomnia

D. Tolbert, A. Karim, C. Cao, 2006, Journal of clinical pharmacology.

SC-52458, an orally active angiotensin II-receptor antagonist: inhibition of blood pressure response to angiotensin II challenges and pharmacokinetics in normal volunteers.

B. Waeber, J. Nussberger, H. Brunner, 1997, Journal of cardiovascular pharmacology.

Oxandrolone disposition and metabolism in man

A. Karim, H. Maibach, R. E. Ranney, 1973, Clinical pharmacology and therapeutics.

Effects of misoprostol on the pharmacokinetics of indomethacin in human volunteers

R. Hunt, R. Hunt, G. Hantsbarger, 1992, Clinical pharmacology and therapeutics.

A. Karim, 1986 .

Simultaneous Assessment of Drug Interactions with Low- and High-Extraction Opioids: Application to Parecoxib Effects on the Pharmacokinetics and Pharmacodynamics of Fentanyl and Alfentanil

E. Kharasch, A. Karim, A. Ibrahim, 2003, Anesthesiology.

The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor

E. Lentjes, A. Cohen, J. Burggraaf, 2000, Clinical pharmacology and therapeutics.

Bidisomide: An Investigational Antiarrhythmic Agent

A. Karim, K. Hashimoto, S. Garthwaite, 1995 .

Use of optical biosensor technology to study immunological cross-reactivity between different sulfonamide drugs.

Ateeq Ahmad, A. Ramakrishnan, A. Karim, 2002, Analytical biochemistry.

Transdermal Absorption: A Unique Opportunity for Drug Delivery

D. Azarnoff, A. Karim, H. Lambert, 1984 .

Stereoselectivity in the metabolism of disopyramide enantiomers in rat and dog.

A. Karim, C. Cook, P. Sollman, 1982, Drug metabolism and disposition: the biological fate of chemicals.

Species Dependent Esterase Activities for Hydrolysis of an Anti-HIV Prodrug Glycovir and Bioavailability of Active SC-48334

A. Karim, G. Schoenhard, C. Cook, 1995, Pharmaceutical Research.

Effects of Age, Sex, and Race on the Safety and Pharmacokinetics of Single and Multiple Doses of Azilsartan Medoxomil in Healthy Subjects

Robert Harrell, A. Karim, Wencan Zhang, 2015, Clinical Pharmacokinetics.

A Pharmacokinetic Study of Intramuscular (IM) Parecoxib Sodium in Normal Subjects

M. Kuss, R. Hubbard, A. Karim, 2001, Journal of clinical pharmacology.

Antiulcer prostaglandin misoprostol: single and multiple dose pharmacokinetic profile.

A. Karim, 1987, Prostaglandins.

Spironolactone Metabolism: Steady‐State Serum Levels of the Sulfur‐Containing Metabolites

M. Rogers, A. Karim, K. Schrode, 1989, Journal of clinical pharmacology.

Metabolism and pharmacokinetics of nufenoxole in animals and humans: an example of stereospecific hydroxylation of an isoquinuclidine ring.

A. Karim, J. Hribar, C. Cook, 1990, Xenobiotica; the fate of foreign compounds in biological systems.

Species differences in the metabolism and disposition of spironolactone.

A. Karim, C. Kook, J. Zagarella, 1976, Drug metabolism and disposition: the biological fate of chemicals.

In Vitro and In Vitro Availability of Spironolactone from Oral Dosage Forms

A. Karim, J. Zagarella, D. Sanvordeker, 1976 .

Spironolactone. I. Disposition and metabolism

A. Karim, J. Hribar, M. Dooley, 1976, Clinical pharmacology and therapeutics.

Isolation and identification of novel sulfur-containing metabolites of spironolactone (Aldactone).

A. Karim, E. Brown, 1972, Steroids.

Self Emulsifying Drug Delivery System

R. Gokhale, A. Karim, Ajit K. Roy, 2012 .

Pharmacokinetic and metabolic fate of potassium canrenoate (SC-14266) in man.

A. Karim, H. Maibach, R. E. Ranney, 1971, Journal of Pharmacy and Science.

Spironolactone: diversity in metabolic pathways.

A. Karim, J. Hribar, C. Markos, 1977, Xenobiotica; the fate of foreign compounds in biological systems.

Spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk.

D. Phelps, A. Karim, 1977, Journal of pharmaceutical sciences.

Spironolactone. II. Bioavailability

T. Hutsell, A. Karim, J. Zagarella, 1976, Clinical pharmacology and therapeutics.

Spironolactone. III. Canrenone—maximum and minimum steady‐state plasma levels

T. Hutsell, A. Karim, M. Dooley, 1976, Clinical pharmacology and therapeutics.

Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human.

J. W. Findlay, R. Bible, A. Karim, 2002, Drug metabolism and disposition: the biological fate of chemicals.

Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption.

M. Vaughn, A. Karim, S. Paulson, 2001, The Journal of pharmacology and experimental therapeutics.

Drug, Meal and Formulation Interactions Influencing Drug Absorption After Oral Administration

D. Fleisher, L. Pao, A. Karim, 1999, Clinical pharmacokinetics.

Transdermal Absorption of Nitroglycerin from Microseal Drug Delivery (MDD) System

A. Karim, 1983, Angiology.

Pharmacokinetics of misoprostol in the elderly, in patients with renal failure and when coadministered with NSAID or antipyrine, propranolol or diazepam.

A. Karim, M. Smith, P. Nicholson, 1990, The Journal of rheumatology. Supplement.

Enantioselective Assays in Comparative Bioavailability Studies of Racemic Drug Formulations: Nice to Know or Need to Know?

A. Karim, 1996, Journal of clinical pharmacology.

Effects of Food and Antacid on Oral Absorption of Misoprostol, A Synthetic Prostaglandin E1 Analog

K. Kowalski, A. Karim, M. Smith, 1989, Journal of clinical pharmacology.

Species differences in the biotransformation of a new antiarrhythmic agent: disopyramide phosphate.

A. Karim, R. E. Ranney, S. Kraychy, 1972, Journal of pharmaceutical sciences.

Comparative binding of disopyramide phosphate and quinidine sulfate to human plasma proteins.

A. Karim, Y. Chien, H. Lambert, 1974, Journal of pharmaceutical sciences.

Reduced Systemic Availability of an Antiarrhythmic Drug, Bidisomide, with Meal Co-administration: Relationship with Region-Dependent Intestinal Absorption

Carol F. Kirchhoff, D. Fleisher, S. Zhou, 1998, Pharmaceutical Research.

Commentary

A. Karim, 1998, Cambridge Quarterly of Healthcare Ethics.

Mechanism of Compound- and Species-Specific Food Effects of Structurally Related Antiarrhythmic Drugs, Disopyramide and Bidisomide

A. Karim, G. Schoenhard, C. Cook, 1998, Pharmaceutical Research.

Absorption and Disposition of a New Antiarrhythmic Agent Bidisomide in Man

K. Kowalski, Margaret E. Smith, A. Karim, 1993, Pharmaceutical Research.

Metabolism of a novel antiarrhythmic agent, bidisomide, in man: use of high resolution mass spectrometry to distinguish desisopropyl bidisomide from desacetyl bidisomide.

A. Karim, J. Hribar, G. Schoenhard, 1995, Xenobiotica; the fate of foreign compounds in biological systems.

Importance of pharmacokinetic and physicochemical data in the discovery and development of novel anti-arrhythmic drugs.

A. Karim, C. Cook, S. McDonald, 1993, Xenobiotica; the fate of foreign compounds in biological systems.

Disopyramide Plasma Concentrations Following Single and Multiple Doses of the Immediate- and Controlled-Release Capsules

A. Karim, Elliot N. Schubert, Thomas S. Burns, 1983, Angiology.

Disopyramide phosphate: pharmacokinetic and pharmacologic relationships of a new antiarrhythmic agent.

A. Karim, R. E. Ranney, F. M. Radzialowski, 1971, Archives internationales de pharmacodynamie et de therapie.

Clinical pharmacokinetics of disopyramide

D. Azarnoff, A. Karim, C. Nissen, 1982, Journal of Pharmacokinetics and Biopharmaceutics.

Food‐induced changes in theophylline absorption from controlled‐release formulations. Part I. Substantial increased and decreased absorption with Uniphyl tablets and Theo‐Dur Sprinkle

A. Karim, L. Wearley, Thomas S. Burns, 1985, Clinical pharmacology and therapeutics.

Verapamil stereoisomerism: Enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both

A. Karim, A. Piergies, 1995, Clinical pharmacology and therapeutics.

Disposition of Misoprostol and its Active Metabolite in Patients With Normal and Impaired Renal Function

W. Keane, C. Halstenson, A. Karim, 1995, Journal of clinical pharmacology.

Pharmacokinetics and metabolism of diphenoxylate in man

M. L. Clark, A. Karim, R. E. Ranney, 1972, Clinical pharmacology and therapeutics.

Biotransformation of diphenoxylate in rat and dog.

W. Trager, A. Karim, G. Garden, 1971, The Journal of pharmacology and experimental therapeutics.

Effects of Celecoxib, a Novel Cyclooxygenase‐2 Inhibitor, on Platelet Function in Healthy Adults: A Randomized, Controlled Trial

P. Isakson, R. Hubbard, A. Karim, 2000, Journal of clinical pharmacology.

The Influence of Parecoxib, a Parenteral Cyclooxygenase-2 Specific Inhibitor, on the Pharmacokinetics and Clinical Effects of Midazolam

E. Kharasch, A. Karim, A. Ibrahim, 2002, Anesthesia and analgesia.

Effects of Parecoxib, a Parenteral COX-2-specific Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Propofol

E. Kharasch, A. Karim, S. Park, 2002, Anesthesiology.

Replicate Study Design in Bioequivalency Assessment, Pros and Cons: Bioavailabilities of the Antidiabetic Drugs Pioglitazone and Glimepiride Present in a Fixed‐Dose Combination Formulation

A. Karim, Zhen Zhao, A. Laurent, 2007, Journal of clinical pharmacology.

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

Q. Mekki, E. Wann, A. Karim, 2008, Clinical therapeutics.

Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis.

R. Hubbard, D. Tolbert, A. Karim, 1999, The Journal of rheumatology.

Placental and milk transfer of disopyramide and metabolites.

A. Karim, C. Kook, J. Campion, 1978, Drug metabolism and disposition: the biological fate of chemicals.

A Randomized, Double-Blind, Parallel Group Comparison of Disopyramide Phosphate* and Quinidine in Patients with Cardiac Arrhythmias

P. W. Willis, A. Karim, R. Wilson, 1983, Angiology.

Effect of Vortioxetine on Cardiac Repolarization in Healthy Adult Male Subjects: Results of a Thorough QT/QTc Study

G. Nomikos, A. Karim, Ying Wang, 2013, Clinical pharmacology in drug development.

Food‐induced changes in theophylline absorption from controlled‐release formulations. Part II. Importance of meal composition and dosing time relative to meal intake in assessing changes in absorption

A. Karim, A. Hurwitz, Thomas S. Burns, 1985, Clinical pharmacology and therapeutics.

PREVENTION OF NSAID-INDUCED GASTRIC ULCER WITH PROSTAGLANDIN ANALOGUES

A. Karim, P. Müller, B. Simon, 1989, The Lancet.

Evaluation of the Impact of UGT Polymorphism on the Pharmacokinetics and Pharmacodynamics of the Novel PPAR Agonist Sipoglitazar

B. Ploeger, R. Urquhart, M. Danhof, 2013, Journal of clinical pharmacology.

Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.

R. Bible, A. Karim, S. Paulson, 2000, Drug metabolism and disposition: the biological fate of chemicals.

Metabolism and Excretion of [14C]Celecoxib in Healthy Male Volunteers

R. Bible, A. Karim, S. Paulson, 2000 .

Age and Gender Effects on the Pharmacokinetics and Pharmacodynamics of Ramelteon, a Hypnotic Agent Acting via Melatonin Receptors MT1 and MT2

D. Greenblatt, J. Harmatz, A. Karim, 2007, Journal of clinical pharmacology.

Celecoxib Does Not Significantly Alter the Pharmacokinetics or Hypoprothrombinemic Effect of Warfarin in Healthy Subjects

R. Hubbard, D. Tolbert, A. Karim, 2000, Journal of clinical pharmacology.

Food-Induced Theophylline Release/Absorption Changes from Controlled-Release Formulations: A Proposed In Vitro Model

A. Karim, J. Streicher, F. Pagone, 1988 .

Theophylline Absorption from Sustained‐Release Products: Comparative Steady‐State Bioavailability of Once‐Daily Theo‐Dur, Theo‐24, and Uniphyl

A. Karim, A. Hurwitz, Thomas S. Burns, 1987, Journal of clinical pharmacology.

Theophylline with food: Theo-24.

A. Karim, 1985, American pharmacy.

Spironolactone metabolism in man studied by gas chromatography-mass spectrometry.

A. Karim, J. Hribar, M. Doherty, 1975, Drug metabolism and disposition: the biological fate of chemicals.

of Racemic Drug Formulations: Is Stereospecific Assay Essential?

A. Karim, C. Madhu, C. Cook, 2004 .

Transdermal Absorption: A Unique Opportunity por Constant Delivery of Nitroglycerin

A. Karim, 1983 .

Effects of Food Intake on the Pharmacokinetics of Azilsartan Medoxomil and Chlorthalidone Alone and in Fixed‐Dose Combination in Healthy Adults

A. Karim, M. Munsaka, C. Dudkowski, 2016, Clinical pharmacology in drug development.

Clinical pharmacology of alogliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of Type 2 diabetes

A. Karim, R. Christopher, 2009, Expert review of clinical pharmacology.

DISPOSITION OF MISOPROSTOL AND ITS ACTIVE METABOLITE IN IMPAIRED HEPATIC FUNCTION

W. Keane, C. Halstenson, A. Karim, 1994, American journal of therapeutics.

Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability.

A. Karim, A. Karim, 1978, Drug metabolism reviews.

A Pharmacokinetic, Pharmacodynamic and Safety Study of Celecoxib in Subjects with Probable Alzheimer's Disease

S. Sainati, P. Zolnouni, D. Tolbert, 2004 .

Q. Mekki, E. Wann, A. Karim, 2008, Clinical therapeutics.